Inferra AI / Company / AORT
Artivion, Inc.
AORT · Health Care
Last earnings Aug 6, 2026
Key results
Achieved revenuequarter
$113.0 million
Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Net incomequarter
$1.3 million
Net income was $1.3 million, or $0.03 per fully diluted share and non-GAAP
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
net income was $10.7 million, or $0.24 per fully diluted share in the second quarter of 2025 Adjusted EBITDA increased 33% to $24.8 million in the second quarter of 2025 compared to $18.6 million in the second quarter of 2024 Exchanged $99.5 million in principal amount of outstanding convertible senior notes due July 1
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
14%
The second quarter was exceptionally strong as we made progress across each of our strategic initiatives while delivering 14% constant currency revenue growth.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenue growth was driven by year-over-year growth in On-X of 24%, stent grafts of 24%, BioGlue of 4%, and Preservation Services of 3%, all compared to the second quarter of 2024.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Total revenuequarter
$113.0 million
Second Quarter 2025 Financial Results Total revenues for the second quarter of 2025 were $113.0 million, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis, both compared to the second quarter of 2024.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Net income for the second quarter of 2025 was $1.3 million, or $0.03 per fully diluted common share, compared to net loss of $(2.1) million, or $(0.05) per fully diluted common share for the second quarter of 2024.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Non-GAAP net incomequarter
$10.7 million
Non-GAAP net income for the second quarter of 2025 was $10.7 million, or $0.24 per fully diluted common share, compared to non-GAAP net income of $2.9 million, or $0.07 per fully diluted common share for the second quarter of 2024.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Achieved revenue | $113.0 million | — | — |
| Net income | $1.3 million | — | — |
| Revenue | 14% | — | — |
| Total revenue | $113.0 million | — | — |
| Non-GAAP net income | $10.7 million | — | — |
Guidance · company-stated
Direction: Raised
“Mackin concluded, Given our strong second quarter performance and continued business momentum, we are raising the midpoints of our full year 2025 constant currency revenue and EBITDA guidance and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth.”
“2025 Financial Outlook Artivion is raising the midpoint of its full year 2025 revenue guidance and now expects constant currency growth of 12% to 14%, compared to the previous range of 11% to 14%.”
“Additionally, Artivion is raising the midpoint of its adjusted EBITDA guidance and now expects growth of between 21% and 28% for the full year 2025 compared to 18% to 28% previously provided.”
Classified from the release's primary full-year outlook statement.
Capital allocation
We also significantly Page 1 of 11 improved our capital structure by retiring all of our $100 million Convertible Senior Notes due July 1, 2025.
The Company s non-GAAP net income, EBITDA, adjusted EBITDA, general, administrative, and marketing, and free cash flows results primarily exclude (as applicable) depreciation and amortization expense, interest income and expense, non-cash compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, business development, integration, and severance income or expense, losses on inducement extinguishment of debt, non-cash interest expense, capital expenditures, and other non-recurring items.
Event summary
Artivion, Inc. Q2 2025 — Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “Mackin concluded, Given our strong second quarter performance and continued business momentum, we are raising the midpoints of our full year 2025 constant currency revenue and EBITDA guidance and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth.”
Revenue: “2025 Financial Outlook Artivion is raising the midpoint of its full year 2025 revenue guidance and now expects constant currency growth of 12% to 14%, compared to the previous range of 11% to 14%.”
Company outlook: “Additionally, Artivion is raising the midpoint of its adjusted EBITDA guidance and now expects growth of between 21% and 28% for the full year 2025 compared to 18% to 28% previously provided.”
Revenue — Raised (“raising”)
“Mackin concluded, Given our strong second quarter performance and continued business momentum, we are raising the midpoints of our full year 2025 constant currency revenue and EBITDA guidance and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth.”
Revenue — Raised (“raising”)
“2025 Financial Outlook Artivion is raising the midpoint of its full year 2025 revenue guidance and now expects constant currency growth of 12% to 14%, compared to the previous range of 11% to 14%.”
Company outlook — Raised (“raising”)
“Additionally, Artivion is raising the midpoint of its adjusted EBITDA guidance and now expects growth of between 21% and 28% for the full year 2025 compared to 18% to 28% previously provided.”
Classified from the release's primary full-year outlook statement.
Capital allocation
We also significantly Page 1 of 11 improved our capital structure by retiring all of our $100 million Convertible Senior Notes due July 1, 2025.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The Company s non-GAAP net income, EBITDA, adjusted EBITDA, general, administrative, and marketing, and free cash flows results primarily exclude (as applicable) depreciation and amortization expense, interest income and expense, non-cash compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, business development, integration, and severance income or expense, losses on inducement extinguishment of debt, non-cash interest expense, capital expenditures, and other non-recurring items.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The Company s adjusted EBITDA expectations for fiscal 2025 exclude potential charges or gains that may be recorded during the fiscal year, relating to, among other things, non-cash compensation business development, integration, and severance income or expense losses on inducement extinguishment of debt and foreign currency revaluations.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The remaining $ 121.0 million consisted of $ 106.8 million of cash consideration and $ 14.2 million paid to settle Endospan debt obligations.
SEC original ↗Artivion, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Additional unamortized debt issuance costs totaling $ 1.1 million related to the New Delayed Draw Term Loan Facility are included in Other long-term assets in the Consolidated Balance Sheets as of December 31, 2025 as a result of the Amendment discussed below.
SEC original ↗Artivion, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Our liquidity needs arise from the funding of our cost of operations and capital expenditures and from debt service on our indebtedness.
SEC original ↗Artivion, Inc. — 10-Q Quarterly report10-QAug 7, 2026
Strategy & priorities
(NYSE AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2025.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The second quarter was exceptionally strong as we made progress across each of our strategic initiatives while delivering 14% constant currency revenue growth.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Page 2 of 11 The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the Company and as a basis for strategic planning.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
, is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons most difficult challenges in treating patients with aortic diseases.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Risks & headwinds
, is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons most difficult challenges in treating patients with aortic diseases.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2025, and our Form 10-Q for the quarter ended June 30, 2025.
SEC original ↗Artivion, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
26 documents- Q2 2026
- 10-QAORT
Aug 7, 2026
- 8-KAORT
Aug 6, 2026
- Q1 2026
- 8-KAORT
May 18, 2026
- 8-KAORT
May 15, 2026
- 10-QAORT
May 8, 2026
- 8-KAORT
May 7, 2026
- Q4 2025
- 10-KAORT
Feb 18, 2026
- 8-KAORT
Feb 12, 2026
- Q3 2025
- 10-QAORT
Nov 7, 2025
- 8-KAORT
Nov 6, 2025
- Q2 2025
- 8-KAORT
Sep 29, 2025
- 8-KAORT
Sep 15, 2025
- 8-KAORT
Aug 11, 2025
- 10-QAORT
Aug 8, 2025
- 8-KAORT
Aug 7, 2025
- Q1 2025
- 8-KAORT
May 29, 2025
- EX-99AORT
May 29, 2025
- 8-KAORT
May 16, 2025
- 8-KAORT
May 14, 2025
- 10-QAORT
May 6, 2025
- 8-KAORT
May 5, 2025
- Q4 2024
- 10-KAORT
Feb 28, 2025
- 8-KAORT
Feb 24, 2025
- Q3 2024
- 8-KAORT
Dec 23, 2024
- 8-KAORT
Dec 9, 2024
- 8-KAORT
Dec 9, 2024
Earnings releases
8 documentsPresentations
0 documentsNo presentations for Artivion, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Artivion, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.